摘要:目的: 观察免费治疗社区精神分裂症患者的疗效。 方法 :纳入贫困家庭精神分裂症患者140例,随机分为免费服药组和对照组,每组70例。随访1年,采用精神分裂症阳性与阴性症状量表(PANSS)\社会功能缺陷量表(SDSS)等评估。 结果 :对实验组与对照组的基线、6个月后及1年后随访的PANSS总分、各因子分、SDSS总分分别进行比较,结果显示基线、6月后均无统计学差异;1年后SDSS总分、PANSS总分、阳性因子分、一般病理因子、思维障碍、偏执因子分差异有显著性;免费治疗组1年后各指标与入组前相比分值降低(P＜001)。 结论 :精神分裂症患者免费服药后精神症状缓解明显,同时其社会功能缺陷也得到改善。Abstract: Objective: To observe the effect of the free treatment on schizophrenics from community. Methods : Totally 140 subjects from poor family were divided into the free treated group and the control group at random. They were followed up for 1 year. The treatment effects were evaluated by PANSS and SDSS. Results : There were no significant difference in all examinations at baseline and after 6 months; at the following end point, significant difference existed in the score of SDSS, the total scores of the PANSS, the positive factor, the general pathology factor, the thinking factor and the paranoid ideation factor between two groups. There was decrease in the scores for all examinations in the free treated group. Conclusion : The symptoms of schizophrenics by free treatment relieve significantly, and the social function improves.
The clinical manifestations of patients with schizophrenia and patients with depression not only have a certain similarity, but also change with the patient's mood, and thus lead to misdiagnosis in clinical diagnosis. Electroencephalogram (EEG) analysis provides an important reference and objective basis for accurate differentiation and diagnosis between patients with schizophrenia and patients with depression. In order to solve the problem of misdiagnosis between patients with schizophrenia and patients with depression, and to improve the accuracy of the classification and diagnosis of these two diseases, in this study we extracted the resting-state EEG features from 100 patients with depression and 100 patients with schizophrenia, including information entropy, sample entropy and approximate entropy, statistical properties feature and relative power spectral density (rPSD) of each EEG rhythm (δ, θ, α, β). Then feature vectors were formed to classify these two types of patients using the support vector machine (SVM) and the naive Bayes (NB) classifier. Experimental results indicate that: ① The rPSD feature vector P performs the best in classification, achieving an average accuracy of 84.2% and a highest accuracy of 86.3%; ② The accuracy of SVM is obviously better than that of NB; ③ For the rPSD of each rhythm, the β rhythm performs the best with the highest accuracy of 76%; ④ Electrodes with large feature weight are mainly concentrated in the frontal lobe and parietal lobe. The results of this study indicate that the rPSD feature vector P in conjunction with SVM can effectively distinguish depression and schizophrenia, and can also play an auxiliary role in the relevant clinical diagnosis.
Objective To systematically review the health state utility values in patients with schizophrenia, and to provide references for subsequent studies on the health economics of schizophrenia. Methods The PubMed, EMbase, The Cochrane Library, Web of Science, CNKI, WanFang Data, and VIP databases were searched from inception to December 1st, 2021 to collect studies on health state utility values in patients with schizophrenia. Two reviewers independently screened literature, extracted data, and assessed the risk of bias of the included studies. Meta-analysis was then performed by Stata 15.0 software. Results A total of 19 studies were included. Patients’ utility values were 0.68 (95%CI 0.59 to 0.77) for direct measures, and 0.77 (95%CI 0.75 to 0.80) and 0.66 (95%CI 0.61 to 0.70) for indirect measures with the EQ-5D-5L and EQ-5D-3L as the primary scales. Utility values varied with measures, tariffs, regions, and populations. Conclusion Studies on health state utility value in schizophrenia are diversified in measurement methods, showing high inter-study heterogeneity. Therefore, it is necessary to promote the study on utility value measurement in schizophrenia in China.
Objective To investigate the difference in first onset age, family history and medication compliance between male and female patients with schizophrenia in communities. Methods We used self-designed questionnaire to survey and analyze 372 cases of schizophrenia between June to August 2014. Results There were no significant differences between male and female schizophrenic patients in the family history, personality before the disease, education level, age, and the onset type and disease course (P > 0.05). The first onset age of male patients [(24.92±8.22) years] was significantly earlier than female patients [(27.02±11.28) years] and the difference was statistically significant (P < 0.05). The number of unmarried male patients (115, 58.97%) was significantly more than unmarried females (81, 45.76%) and the difference was statistically significant (P < 0.05). The full medication compliance rate of female patients (127, 71.75%) was significantly better than that of male patients (115, 58.97%) (P < 0.05). Conclusion The first onset age, marital status and medication compliance are significantly different between the two genders of patients with schizophrenia, which indicates that prevention, treatment and recovery measures for male and female patients should be differentiated.
The study aims to investigate whether there is difference in pre-treatment white matter parameters in treatment-resistant and treatment-responsive schizophrenia. Diffusion tensor imaging (DTI) was acquired from 60 first-episode drug-naïve schizophrenia (39 treatment-responsive and 21 treatment-resistant schizophrenia patients) and 69 age- and gender-matched healthy controls. Imaging data was preprocessed via FSL software, then diffusion parameters including fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD) and radial diffusivity (RD) were extracted. Besides, structural network matrix was constructed based on deterministic fiber tracking. The differences of diffusion parameters and topology attributes between three groups were analyzed using analysis of variance (ANOVA). Compared with healthy controls, treatment-responsive schizophrenia showed altered white matter mainly in anterior thalamus radiation, splenium of corpus callosum, cingulum bundle as well as superior longitudinal fasciculus. While treatment-resistant schizophrenia patients showed white matter abnormalities in anterior thalamus radiation, cingulum bundle, fornix and pontine crossing tract relative to healthy controls. Treatment-resistant schizophrenia showed more severe white matter abnormalities in anterior thalamus radiation compared with treatment-responsive patients. There was no significant difference in white matter network topological attributes among the three groups. The performance of support vector machine (SVM) showed accuracy of 63.37% in separating the two patient subgroups (P = 0.04). In this study, we showed different patterns of white matter alterations in treatment-responsive and treatment-resistant schizophrenia compared with healthy controls before treatment, which may help guiding patient identification, targeted treatment and prognosis improvement at baseline drug-naïve state.
ObjectiveTo explore the effects of drug management skill training on lightening the family burden of schizophrenic patients in their recovery period. MethodsBetween December 2011 and December 2013, 101 patients with schizophrenia were randomly divided into experimental group (n=56) and control group (n=45). The experimental group was given drug management skill training, while the control group only received routine follow-up. The course of the research was six months. Both groups were assessed by the positive and negative syndrome scale on patients' psychological symptoms, and family burden scale of diseases was used to assess the burden of the family. ResultsCompared with the controls, patients in the experimental group improved more in their positive symptoms (t=2.692, P=0.008), negative symptoms (t=2.729, P=0.008), general psychopathology symptoms (t=3.231, P=0.002) and the whole psychiatric symptoms (t=3.870, P<0.001). Moreover, the degree of patients' symptom improvement was positively correlated with the degree of family burden lightening (r=0.44, P<0.001). ConclusionFor patients with schizophrenia, reasonable drug management skill training can effectively improve patients' medication compliance, promote treatment effect and lighten family burden.
目的 探讨阿立哌唑治疗难治性精神分裂症的疗效与安全性。 方法 对2006年12月-2008年12月收治的120例难治性精神分裂症患者，随机分为阿立哌唑治疗组（60例）和氯氮平治疗组（60例），疗程8周。于治疗前（0周）、治疗后第1、2、4、8周末，评定阳性和阴性症状量表（PANSS）、治疗中需处理的不良反应症状量表（TESS），分析疗效及安全性。 结果 ①阿立哌唑组PANSS总分、阳性症状分、阴性症状分、一般病理分从治疗第2周末起，较治疗前下降（Plt;0.05）；氯氮平组PANSS总分、阳性症状分、一般病理分从治疗第2周末起，阴性症状分从第4周末起，较治疗前下降（Plt;0.05）；阿立哌唑组各时点的PANSS总分，均与氯氮平组无差异（Pgt;0.05）；自第2周末起，阿立哌唑组阴性症状分低于氯氮平组（Plt;0.05），而阳性症状分高于氯氮平组（Plt;0.05）。②治疗第8周末，阿立哌唑组有效率（46.7％）与氯氮平组（50.0％）无统计学意义（Pgt;0.05）。③阿立哌唑组不良反应发生率（36.7%）低于氯氮平组（63.3%），有统计学意义（Plt;0.05）；氯氮平组的体重增加、活动减退等的发生率高于阿立哌唑组（P＜0.05），而阿立哌唑组恶心、肌张力增高等发生率高于氯氮平组（Plt;0.05）。 结论 阿立哌唑在难治性精神分裂症的治疗中，疗效与氯氮平相当，而不良反应较少。
ObjectiveTo explore family care and its influence on the life quality of schizophrenia patients. MethodsBetween September 2011 and March 2012, 101 schizophrenia patients were investigated with Questionnaire of Family Care and Quality of Life Inventory and were divided into two groups in order to compare their life quality. According to the scores of Questionnaire of Family Care, 56 subjects were in support group and 45 subjects were in control group. ResultsAmong the 101 patients, 55.45% had good family care and 44.55% had not. In the support group, there was no significant correlation between family care and life quality in the first month and the third month (r=0.023, P=0.894; r=-0.072, P=0.587), while there was a significant correlation between family care and life quality in the sixth month (r=-0.322, P=0.032). In the control group, there was no significant differences in the score of family care and life quality in the first, third and sixth month (r=0.021, P=0.893; r=0.114, P=0.482; r=1.863, P=0.226). ConclusionLong-term family care is significantly correlated with the life quality of schizophrenia patients. If schizophrenic patients get more poor family care, they will have lower life quality. It's important to create a good and comfortable environment for the patients.